Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1975 1
1982 1
1984 2
1985 1
1986 2
1987 1
1988 1
1989 1
1990 1
1991 1
1992 2
1993 5
1994 3
1995 4
1997 5
1998 4
1999 10
2000 17
2001 14
2002 17
2003 23
2004 35
2005 31
2006 51
2007 50
2008 55
2009 50
2010 84
2011 85
2012 93
2013 89
2014 81
2015 100
2016 105
2017 108
2018 122
2019 121
2020 196
2021 280
2022 348
2023 262
2024 69

Text availability

Article attribute

Article type

Publication date

Search Results

2,218 results

Results by year

Filters applied: . Clear all
Page 1
Combined oral contraceptives: venous thrombosis.
de Bastos M, Stegeman BH, Rosendaal FR, Van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, Dekkers OM. de Bastos M, et al. Cochrane Database Syst Rev. 2014 Mar 3;2014(3):CD010813. doi: 10.1002/14651858.CD010813.pub2. Cochrane Database Syst Rev. 2014. PMID: 24590565 Free PMC article. Review.
The relative risk of venous thrombosis for combined oral contraceptives with 30-35 mug ethinylestradiol and gestodene, desogestrel, cyproterone acetate, or drospirenone were similar and about 50-80% higher than for combined oral contraceptives with levonorgestrel. . …
The relative risk of venous thrombosis for combined oral contraceptives with 30-35 mug ethinylestradiol and gestodene, desogestrel, c …
Premenstrual disorders.
Yonkers KA, Simoni MK. Yonkers KA, et al. Am J Obstet Gynecol. 2018 Jan;218(1):68-74. doi: 10.1016/j.ajog.2017.05.045. Epub 2017 May 29. Am J Obstet Gynecol. 2018. PMID: 28571724 Review.
Pharmacological and metabolic effects of drospirenone as a progestin-only pill compared to combined formulations with estrogen.
Regidor PA, Mueller A, Mayr M. Regidor PA, et al. Womens Health (Lond). 2023 Jan-Dec;19:17455057221147388. doi: 10.1177/17455057221147388. Womens Health (Lond). 2023. PMID: 36744531 Free PMC article. Review.
Ethinylestradiol, an inhibitor of CYP metabolic enzymes, changes the pharmacokinetics of drospirenone, leading to a higher drospirenone exposure with ethinylestradiol/drospirenone compared to the drospirenone-only preparation. ...There is …
Ethinylestradiol, an inhibitor of CYP metabolic enzymes, changes the pharmacokinetics of drospirenone, leading to a higher …
Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone.
Klipping C, Duijkers I, Mawet M, Maillard C, Bastidas A, Jost M, Foidart JM. Klipping C, et al. Contraception. 2021 Apr;103(4):213-221. doi: 10.1016/j.contraception.2021.01.001. Epub 2021 Jan 9. Contraception. 2021. PMID: 33428907 Free article. Clinical Trial.
OBJECTIVES: To evaluate the effect on endocrine and metabolic parameters of a new combined oral contraceptive (COC) containing estetrol (E4) and drospirenone (DRSP). STUDY DESIGN: Randomized, open-label, controlled, 3-arm, parallel study. Healthy subjects received either E …
OBJECTIVES: To evaluate the effect on endocrine and metabolic parameters of a new combined oral contraceptive (COC) containing estetrol (E4) …
Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk.
Morimont L, Haguet H, Dogné JM, Gaspard U, Douxfils J. Morimont L, et al. Front Endocrinol (Lausanne). 2021 Dec 9;12:769187. doi: 10.3389/fendo.2021.769187. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34956081 Free PMC article. Review.
Numerous studies assessed the impact of estroprogestative combinations on hemostasis and demonstrated that women under COC suffered from resistance towards activated protein C (APC). ...In this year 2021, a novel COC based on a native estrogen, i.e., estetrol, will be intr …
Numerous studies assessed the impact of estroprogestative combinations on hemostasis and demonstrated that women under COC suffered f …
A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception.
Dragoman MV, Tepper NK, Fu R, Curtis KM, Chou R, Gaffield ME. Dragoman MV, et al. Int J Gynaecol Obstet. 2018 Jun;141(3):287-294. doi: 10.1002/ijgo.12455. Epub 2018 Feb 22. Int J Gynaecol Obstet. 2018. PMID: 29388678 Free PMC article. Review.
OBJECTIVE: To evaluate the comparative risks of VTE associated with the use of low-dose (less than 50 mug ethinyl estradiol) COCs containing different progestogens. SEARCH STRATEGY: PubMed and the Cochrane Library were searched from database inception through Septem …
OBJECTIVE: To evaluate the comparative risks of VTE associated with the use of low-dose (less than 50 mug ethinyl estradiol) C …
Estetrol-drospirenone combination oral contraceptive: North American phase 3 efficacy and safety results.
Creinin MD, Westhoff CL, Bouchard C, Chen MJ, Jensen JT, Kaunitz AM, Achilles SL, Foidart JM, Archer DF. Creinin MD, et al. Contraception. 2021 Sep;104(3):222-228. doi: 10.1016/j.contraception.2021.05.002. Epub 2021 May 15. Contraception. 2021. PMID: 34000251 Free article. Clinical Trial.
OBJECTIVE: To assess efficacy, cycle control, and safety of an oral contraceptive containing estetrol (E4) 15 mg and drospirenone (DRSP) 3 mg. STUDY DESIGN: Women aged 16 to 50 years with a body mass index 35 kg/m(2) enrolled in this multicenter, open-label, 13-cycle, phas …
OBJECTIVE: To assess efficacy, cycle control, and safety of an oral contraceptive containing estetrol (E4) 15 mg and drospirenone (DR …
Treatment of lean PCOS teenagers: a follow-up comparison between Myo-Inositol and oral contraceptives.
Pkhaladze L, Russo M, Unfer V, Nordio M, Basciani S, Khomasuridze A. Pkhaladze L, et al. Eur Rev Med Pharmacol Sci. 2021 Dec;25(23):7476-7485. doi: 10.26355/eurrev_202112_27447. Eur Rev Med Pharmacol Sci. 2021. PMID: 34919250 Free article. Clinical Trial.
They were treated for 3 months either with oral contraceptive pills (OCP) drospirenone/ethinylestradiol (group A), myo-Inositol (myo-Ins) (group B), or OCP plus myo-Ins (group C). ...
They were treated for 3 months either with oral contraceptive pills (OCP) drospirenone/ethinylestradiol (group A), myo-Inosito …
Kākāpō.
Foster Y, Robertson BC. Foster Y, et al. Curr Biol. 2022 Oct 24;32(20):R1066-R1067. doi: 10.1016/j.cub.2022.07.011. Curr Biol. 2022. PMID: 36283363 Free article.
Yasmin Foster and Bruce C. Robertson introduce the enigmatic and critically endangered kakapo - the world's only flightless parrot....
Yasmin Foster and Bruce C. Robertson introduce the enigmatic and critically endangered kakapo - the world's only flightless parrot... …
Efficacy of dienogest vs combined oral contraceptive on pain associated with endometriosis: Randomized clinical trial.
El Taha L, Abu Musa A, Khalifeh D, Khalil A, Abbasi S, Nassif J. El Taha L, et al. Eur J Obstet Gynecol Reprod Biol. 2021 Dec;267:205-212. doi: 10.1016/j.ejogrb.2021.10.029. Epub 2021 Oct 30. Eur J Obstet Gynecol Reprod Biol. 2021. PMID: 34826668 Clinical Trial.
OBJECTIVE: To compare the efficacy of dienogest with the combined oral contraceptive pill (COC) Yasmin for the control of endometriosis-associated pelvic pain. STUDY DESIGN: Seventy women with endometriosis-associated chronic pelvic pain, dysmenorrhoea or both for >6 mo …
OBJECTIVE: To compare the efficacy of dienogest with the combined oral contraceptive pill (COC) Yasmin for the control of endometrios …
2,218 results